RE:RE:RE:RE:RE:RE:RE:RE:RE:RE:RE:NASH market and competition Yea, e-mail Paul to check all the drawers. Maybe Luc had one lying around that they forgot about.
Right now just coming up with a protocol for the next trial would cost cents, add value and be 100x easier than what you suggest. Let's get thru that milestone first.
If you think of the company as 3 projects a reset on sales, cancer and NASH then almost everywhere you look there has been examples of great planning, great execution and great communication. I understand for the most part what Paul wants to do with sales, I don't know if he succeeds but I get it. I understand exactly what Christian plans with cancer, I see execution that exceeds expectations. The NASH program is less clear both from a regulatory and clinical perspective. I don't buy into the idea that ineptitude suddenly creeps in with the NASH program when it doesn't exist with the other programs. You don't have two years (and ongoing) on one stage of the regulatory process without that signalling a complex process. The ongoing uncertainty from a regulatory perspective feeds the ongoing uncertainty from the clinical perspective. The program will get clarity when the protocol is announced, we will understand exactly the strengths and weaknesses then. We may as well join the market in wait and see mode.
jeffm34 wrote:
Do you know what would make investors aware of TH's NASH program. A big licensing agreement with a company like Gilead to develop Egrifta in NASH. If the company's prospects for NASH are as bright as some here think, there are companies lining up to partner with TH. Then the company can focus on the bigger opportunity in oncology.
SPCEO1 wrote: I am not sure very many investors are even aware that TH has a ready to proceed letter from the FDA for NASH. So, it is not that they are wrong, it is that they just are unaware. And that is the company's fault for not selling the news well enough (and then quickly stomping on the news with the OO). And the sales job needed to begin long, long before the offering. The news of the FDA's approval for the company to proceed with the phase III NASH trial should have been something investors were waiting with baited breath for it to be released. But, just as in September when the company actually had a stunningly good conference call to announce the good news that they were moving into general NASH, very few people heard it and the stock reacted with a big yawn. They failed to lay the proper groundwork for that decision and it was ignored. They finally got the FDA's backing and gave no time for that to sink in before doing the offering which was led by cancer investors, rather than NASH investors.
The company really does have something of interest in NASH and neither you or anyone else has yet to make a cogent case to lead me to think otherwise. In fact, the case just keeps getting better for Egrifta in NASH as Dr. Grinspoon keeps adding more and more science to the equation.
The whole NASH thing has been a failure in marketing the opportunity to investors and that failure is made all the worse because it occurred in a huge bull market where any crazy idea has been well recieved by retail investors and even some institutional ones too.
jeffm34 wrote: So are you saying that every single investor is wrong except for a handful of people posting on this board?
scarlet1967 wrote: Believe me I haven't missed that and it's real so is the reason why.
jeffm34 wrote: You are missing the only thing that matters. The current share price the market has ascribed to TH's NASH program. It's not an oversight by investors. It's a reality.
scarlet1967 wrote: am I missing something here?